Skip to main content
    G

    Gossamer Bio Inc (GOSS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.98
    +0.01 (+0.09%)

    Market Cap: $67.10M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Gossamer Bio Inc (GOSS) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Gossamer Bio (GOSS) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Gossamer Bio reported EPS of -$1.19, above the -$5.55 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    32%(10/31)
    Avg Surprise
    -7.10%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$3.23
    Range-$6.13 - -$1.60
    9 analysts
    Revenue Consensus
    $3.59M
    RangeN/A
    9 analysts
    Reports May 17, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$6.39
    Range-$7.20 - -$5.60
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$5.07-26.1%
    60d ago-$5.07-26.1%
    30d ago-$5.60-14.1%
    7d ago-$6.40+0.2%
    Current-$6.39
    Revenue Consensus
    $840.00K
    RangeN/A
    5 analysts

    Next Report

    GOSS has an expected report date of Mar 15, 2027.

    GOSS Earnings Call

    The latest GOSS earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 31 quarters below that had an estimate, GOSS beat 10, missed 16 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $38.43M, up 189.2% from $13.29M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.19-$5.55-$7.43 - $0.80+78.56%BeatN/A50 up, 0 downNov 10, 2026$38.43M
    Jun 30, 2026-$0.20-$0.10-$0.24 - -$0.04-100.00%MissN/A71 up, 1 downAug 13, 2026$9.24M
    Mar 31, 2026-$0.20-$0.17-$0.25 - -$0.05-17.65%MissN/A7N/AMay 18, 2026$16.95M
    Dec 31, 2025-$0.21-$0.19-$0.25 - -$0.13-13.51%MissN/A91 up, 3 downMar 17, 2026$13.80M
    Sep 30, 2025-$0.21-$0.19-$0.22 - -$0.17-10.53%MissN/A72 up, 4 downNov 5, 2025$13.29M
    Jun 30, 2025-$0.17-$0.18-$0.20 - -$0.16+5.56%Beat-177.3%94 up, 1 downAug 5, 2025$11.49M
    Mar 31, 2025-$0.16-$0.18-$0.22 - -$0.17+11.11%BeatN/A70 up, 0 downMay 15, 2025$9.89M
    Dec 31, 2024-$0.15-$0.17-$0.21 - -$0.08+10.71%BeatN/A84 up, 3 downMar 13, 2025$9.38M
    Sep 30, 2024-$0.14-$0.14-$0.22 - -$0.010.00%In lineN/A100 up, 0 downNov 7, 2024$9.48M
    Jun 30, 2024$0.22$0.27-$0.20 - $0.55-18.52%MissN/A100 up, 0 downAug 12, 2024$95.84M
    Mar 31, 2024-$0.19-$0.19-$0.23 - -$0.150.00%In lineN/A90 up, 0 downMay 7, 2024N/A
    Dec 31, 2023-$0.21-$0.21-$0.29 - -$0.170.00%In lineN/A80 up, 0 downMar 5, 2024$6.78M
    Sep 30, 2023-$0.21-$0.27-$0.65 - -$0.18+22.22%BeatN/A100 up, 0 downNov 9, 2023N/A
    Jun 30, 2023-$0.45-$0.50-$0.60 - -$0.41+10.00%BeatN/A101 up, 0 downAug 8, 2023N/A
    Mar 31, 2023-$0.52-$0.54-$0.62 - -$0.41+3.70%BeatN/A100 up, 0 downMay 9, 2023N/A
    Dec 31, 2022-$0.59-$0.62-$0.67 - -$0.57+4.84%BeatN/A130 up, 0 downMar 17, 2023N/A
    Sep 30, 2022-$0.65-$0.66-$0.84 - -$0.56+1.52%BeatN/A121 up, 0 downNov 3, 2022N/A
    Jun 30, 2022-$0.74-$0.69-$0.79 - -$0.44-7.25%MissN/A90 up, 0 downAug 9, 2022N/A
    Mar 31, 2022-$0.76-$0.76-$0.86 - -$0.690.00%In lineN/A81 up, 0 downMay 10, 2022N/A
    Dec 31, 2021-$0.74-$0.74-$0.82 - -$0.640.00%In lineN/A6N/AMar 3, 2022N/A
    Sep 30, 2021-$0.80-$0.77-$0.82 - -$0.74-3.90%MissN/A50 up, 0 downNov 8, 2021N/A
    Jun 30, 2021-$0.80-$0.76-$0.79 - -$0.73-5.26%MissN/A4N/AAug 9, 2021N/A
    Mar 31, 2021-$0.78-$0.74-$0.82 - -$0.70-5.41%MissN/A4N/AMay 6, 2021N/A
    Dec 31, 2020-$0.88-$0.79-$0.92 - -$0.65-11.39%MissN/A6N/AFeb 25, 2021N/A
    Sep 30, 2020-$0.80-$0.85-$0.95 - -$0.75+5.88%BeatN/A6N/ANov 10, 2020N/A
    Jun 30, 2020-$1.00-$0.86-$1.07 - -$0.70-16.28%MissN/A6N/AAug 11, 2020N/A
    Mar 31, 2020-$0.87-$0.75-$0.85 - -$0.75-16.00%MissN/A5N/AMay 12, 2020N/A
    Dec 31, 2019-$0.89-$0.86-$1.07 - -$0.73-3.49%MissN/A6N/AMar 24, 2020N/A
    Sep 30, 2019-$0.80-$0.68-$0.71 - -$0.68-17.65%MissN/A2N/ANov 12, 2019N/A
    Jun 30, 2019-$0.74-$0.43N/A-72.09%MissN/A1N/AAug 8, 2019N/A
    Mar 31, 2019-$0.90-$0.58N/A-55.17%MissN/A2N/AMay 14, 2019N/A
    Dec 31, 2018-$18.23-$1.00-$1.45 - -$0.17N/AN/AN/A3N/AFeb 12, 2019N/A
    Sep 30, 2018-$0.93N/AN/AN/AN/AN/AN/AN/AOct 11, 2018N/A
    Last 33 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.75, after -$0.26 the year before. It was -$19.16 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.75N/A
    Dec 31, 2024-$0.26N/A
    Dec 31, 2023-$1.39N/A
    Dec 31, 2022-$2.74N/A
    Dec 31, 2021-$3.12N/A
    Dec 31, 2020-$3.55N/A
    Dec 31, 2019-$3.33N/A
    Dec 31, 2018-$19.16N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,500 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20265,51211
    2025Q1Mar 31, 20258,65414

    2026Q1 Earnings Call

    Opening remarks

    Bryan Giraudo Chief Operating Officer and Chief Financial Officer Good morning, and thank you for joining us. Before we begin, I'd like to remind listeners that today's discussion includes forward-looking statements, including statements regarding our regulatory plans, potential NDA submission and approval timing, commercialization, expectations, cash runway, capital structure and the potential therapeutic benefit and future developments of seralutinib. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings and today's press release for discussions of these risks. We undertake no obligation to update these forward-looking statements, except as required by law. We are very excited this morning to have on our call today, Faheem Hasnain, Caryn Peterson, Dr. Rob Roscigno. Additionally, we have Dr. Jean-Marie Bruey, Dr. Rainer Zimmermann, Dr. Megan Flynn, Dr. Robin Osterhout; and Bob Smith, our Chief Commercial Officer, to speak about our exciting results this morning. Today, we plan to cover 3 topics: First, a regulatory update, including our Type B pre-NDA meeting; Secondly, we will discuss results from our PROSERA CT FRI substudy; and third, an update on our capital structure, including the convertible note exchange. Our financial results for the first quarter of 2026 are included in this press release, and I will come back to briefly discuss these at the end of the call. With that overview, let me hand it over to Faheem to discuss our recent progress. Faheem?

    Faheem Hasnain Chief Executive Officer Yes. Thanks, Bryan, and good morning, everybody. In February, we reported top line results from PROSERA, our Phase III study of seralutinib in patients with PAH. At a high level, PROSERA showed a clinically meaningful placebo-adjusted improvement of 13.3 meters in 6-minute walk distance at week 24, with patients on seralutinib improving 28.2 meters from baseline versus 13.5 meters on placebo and a p-value of 0.032. That p-value met the traditional 0.05 threshold for statistical significance, but it did not meet the prespecified 0.025 alpha threshold. At the same time, all 4 key secondary endpoints favored seralutinib over placebo, and we saw a stronger effect in the prespecified risk-enriched subgroup. Taken together, we believe the totality of the PROSERA data supports a real and clinically meaningful treatment signal. Now since the PROSERA top line readout, we've been focused on 3 work streams in parallel. First, we engaged with the FDA on the path forward for seralutinib. That process advanced from the previously disclosed Type C meeting to a Type B pre-NDA meeting, which is the most formal pre-submission meeting type. The meeting has been confirmed as in person and the briefing book has been submitted. Caryn will cover that in more detail shortly.

    Frequently Asked Questions About GOSS

    When is Gossamer Bio's next earnings date?

    Gossamer Bio's next earnings report is expected for Mar 15, 2027.

    Did GOSS beat earnings estimates last quarter?

    Yes. Gossamer Bio reported EPS of -$1.19 for the quarter ended Sep 30, 2026, above the -$5.55 estimate, a 78.56% surprise.

    What EPS do analysts expect from GOSS next quarter?

    The consensus EPS estimate for Gossamer Bio for the quarter ending Dec 31, 2026 is -$3.23 from 9 analysts, with estimates from -$6.13 to -$1.60.

    How often does GOSS beat earnings estimates?

    Gossamer Bio beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -4.47%.